Phathom Pharmaceuticals, Inc.
$4.66-$0.42 (-8.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $786.4M
- P/E
- -3.6x
- EV / EBITDA
- -5.7x
- Revenue
- $175.1M
- Net margin
- -126.3%
- ROCE
- -125.9%
Price chart
Technical chartScreen technicals →-67.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -36.3%
- 3M
- -45.8%
- 6M
- -60.7%
- 1Y
- -67.5%
- 5Y
- -76.8%
52-week range
Day change -$0.42 (-8.3%) from $5 to $5 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PHAT, bought on each weekday since 2021.
News & filings
What Phathom Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Read moreShow less
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 71.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $786.4M
- P/E
- -3.6x
- P/B
- -1.8x
- EV / EBITDA
- -5.7x
- EV / Sales
- 5.0x
- P/S
- 4.5x
- 52-week high
- $18.08
- 52-week low
- $4.66
Profitability
- Operating margin
- -91.4%
- Net margin
- -126.3%
- EBITDA margin
- -87.1%
- ROE
- 50.5%
- ROCE
- -125.9%
- ROA
- -85.4%
- Asset turnover
- 0.68
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $175.1M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 216.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -33.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$167.0M
Solvency
- Current ratio
- 1.73
- Debt / Equity
- -0.48
- Debt / Assets
- 0.82
- CFO / Net profit
- 0.75
- Cash / Market cap
- 16.5%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $175.1M |
| Cost of revenue | $22.6M |
| Gross profit | $152.5M |
| Operating expenses | $312.5M |
| Research and development | $32.8M |
| Selling, general and administrative | $279.7M |
| Operating income | -$160.0M |
| Interest and other | -$61.3M |
| Pretax income | -$221.3M |
| Tax and other | $0.00 |
| Net income | -$221.3M |
Revenue and net profit
Revenue grew 216.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$197.7M |
| FY2023 | $682.0k | -$201.6M |
| FY2024 | $55.3M | -$334.3M |
| FY2025 | $175.1M | -$221.2M |
Cash flows
FY2025: -$166.8M from operations, -$167.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$146.5M | -$147.6M |
| FY2023 | -$137.6M | -$139.2M |
| FY2024 | -$266.8M | -$266.9M |
| FY2025 | -$166.8M | -$167.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $175.1M+216.9%1Y
- EBITDA
- -$152.5M
- Net profit
- -$221.2M
- Cash from operations
- -$166.8M
- Free cash flow
- -$167.0M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $175.1M | -$152.5M | -$221.2M | -$167.0M | 50.5% | +216.9% | -33.8% |
Monthly returns
Month-by-month returns of PHAT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $259.1M |
| Current assets | $229.0M |
| Non-current assets | $30.2M |
| Liabilities | $697.3M |
| Current liabilities | $132.0M |
| Non-current liabilities | $565.3M |
| Equity | -$438.2M |
| Paid-in capital | $1.0B |
| Retained earnings | -$1.5B |
| Treasury stock | $0.00 |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PHAT highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Sana Biotechnology, Inc., Replimune Group, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHATthis company | $786.4M | -3.6x | -1.8x | 50.5% | -5.7x |
| Sana Biotechnology, Inc.SANA | $823.7M | -3.4x | 5.1x | -151.8% | -4.3x |
| Replimune Group, Inc.REPL | $815.0M | -3.3x | 2.0x | -59.5% | -3.3x |
| Esperion Therapeutics, Inc.ESPR | $805.8M | — | — | 7.5% | 13.9x |
| Lumexa Imaging Holdings, Inc.LMRI | $791.7M | -16.8x | 1.4x | -8.0% | 12.0x |
| Eton Pharmaceuticals, Inc.ETON | $791.6M | -172.1x | 30.3x | -17.6% | 249.0x |
| Kura Oncology, Inc.KURA | $778.6M | — | 4.5x | -160.0% | — |
| Geron CorporationGERN | $776.2M | -9.3x | 3.4x | -37.0% | -16.5x |
| BioAge Labs, Inc.BIOA | $756.6M | -9.4x | 2.8x | -29.6% | -7.2x |
| Peer median | — | -9.3x | 3.4x | -33.3% | -3.3x |
Year-to-date ROI
PHAT since 1 January, against earlier years.
Historical volatility
PHAT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2023 | -24604.4% |
| FY2024 | -502.2% |
| FY2025 | -91.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $175.1M |
| Cost of revenueCost Of Revenue | $22.6M |
| Gross profitGross Profit | $152.5M |
| Operating expensesOperating Expense | $312.5M |
| Research and developmentResearch And Development | $32.8M |
| Selling, general and administrativeSelling General And Administration | $279.7M |
| Total expensesTotal Expenses | $335.1M |
| Operating incomeOperating Income | -$160.0M |
| Interest and other | |
| Pretax incomePretax Income | -$221.3M |
| Tax | |
| Net incomeNet Income | -$221.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $259.1M |
| Current assetsCurrent Assets | $229.0M |
| Non-current assetsTotal Non Current Assets | $30.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $697.3M |
| Current liabilitiesCurrent Liabilities | $132.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $565.3M |
| EquityTotal Equity Gross Minority Interest | -$438.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$166.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$166.8M |
| Net income, continuing operationsNet Income From Continuing Operations | -$221.3M |
| Depreciation and amortisationDepreciation And Amortization | $630.0k |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $630.0k |
| Stock-based compensationStock Based Compensation | $28.7M |
| Provision and write off of assetsProvisionand Write Offof Assets | $280.0k |
| Change in working capitalChange In Working Capital | -$12.4M |
| Other non-cash itemsOther Non Cash Items | $37.2M |
| Investing cash flowInvesting Cash Flow | -$230.0k |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$230.0k |
| Capital expenditureCapital Expenditure | -$230.0k |
| Purchase of PP&EPurchase Of PPE | -$230.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$230.0k |
| Financing cash flowFinancing Cash Flow | -$290.0k |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$290.0k |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $1.6M |
| Other financing chargesNet Other Financing Charges | -$1.9M |
| Change in cashChanges In Cash | -$167.3M |
| Cash at the start of the yearBeginning Cash Position | $300.1M |
| Cash at the end of the yearEnd Cash Position | $132.8M |
| Free cash flowFree Cash Flow | -$167.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Phathom Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing217% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read